Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Splicing: is there an alternative contribution to Parkinson's disease?

La Cognata V, D'Agata V, Cavalcanti F, Cavallaro S.

Neurogenetics. 2015 Oct;16(4):245-63. doi: 10.1007/s10048-015-0449-x. Epub 2015 May 16. Review.

2.

Identification and molecular characterization of Parkin in Clonorchis sinensis.

Bai X, Kim TI, Lee JY, Dai F, Hong SJ.

Korean J Parasitol. 2015 Feb;53(1):65-75. doi: 10.3347/kjp.2015.53.1.65. Epub 2015 Feb 27.

3.

Alternative splicing generates different parkin protein isoforms: evidences in human, rat, and mouse brain.

Scuderi S, La Cognata V, Drago F, Cavallaro S, D'Agata V.

Biomed Res Int. 2014;2014:690796. doi: 10.1155/2014/690796. Epub 2014 Jul 16.

4.

Increasing the Coding Potential of Genomes Through Alternative Splicing: The Case of PARK2 Gene.

La Cognata V, Iemmolo R, D'Agata V, Scuderi S, Drago F, Zappia M, Cavallaro S.

Curr Genomics. 2014 Jun;15(3):203-16. doi: 10.2174/1389202915666140426003342.

5.

α-Synuclein and mitochondrial dysfunction in Parkinson's disease.

Mullin S, Schapira A.

Mol Neurobiol. 2013 Apr;47(2):587-97. doi: 10.1007/s12035-013-8394-x. Epub 2013 Jan 30. Review.

6.

Modification by ubiquitin-like proteins: significance in apoptosis and autophagy pathways.

Cajee UF, Hull R, Ntwasa M.

Int J Mol Sci. 2012;13(9):11804-31. doi: 10.3390/ijms130911804. Epub 2012 Sep 19. Review.

7.

Preconditioning involves selective mitophagy mediated by Parkin and p62/SQSTM1.

Huang C, Andres AM, Ratliff EP, Hernandez G, Lee P, Gottlieb RA.

PLoS One. 2011;6(6):e20975. doi: 10.1371/journal.pone.0020975. Epub 2011 Jun 8.

8.

Genome-wide analysis of copy number variants in age-related macular degeneration.

Meyer KJ, Davis LK, Schindler EI, Beck JS, Rudd DS, Grundstad AJ, Scheetz TE, Braun TA, Fingert JH, Alward WL, Kwon YH, Folk JC, Russell SR, Wassink TH, Stone EM, Sheffield VC.

Hum Genet. 2011 Jan;129(1):91-100. doi: 10.1007/s00439-010-0904-6. Epub 2010 Oct 28.

9.

Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications.

Huang Q, Figueiredo-Pereira ME.

Apoptosis. 2010 Nov;15(11):1292-311. doi: 10.1007/s10495-010-0466-z. Review.

10.

Identification and characterization of a novel endogenous murine parkin mutation.

Ramsey CP, Giasson BI.

J Neurochem. 2010 Apr;113(2):402-17. doi: 10.1111/j.1471-4159.2010.06605.x. Epub 2010 Jan 20.

11.

Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies.

Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I, Janakiraman M, Schultz N, Hanrahan AJ, Pao W, Ladanyi M, Sander C, Heguy A, Holland EC, Paty PB, Mischel PS, Liau L, Cloughesy TF, Mellinghoff IK, Solit DB, Chan TA.

Nat Genet. 2010 Jan;42(1):77-82. doi: 10.1038/ng.491. Epub 2009 Nov 29.

12.

The multiple mechanisms of amyloid deposition: the role of parkin.

Mena MA, Rodríguez-Navarro JA, de Yébenes JG.

Prion. 2009 Jan-Mar;3(1):5-11. Epub 2009 Jan 9. Review.

13.

The ring between ring fingers (RBR) protein family.

Eisenhaber B, Chumak N, Eisenhaber F, Hauser MT.

Genome Biol. 2007;8(3):209. Review.

14.

Loss of locus coeruleus neurons and reduced startle in parkin null mice.

Von Coelln R, Thomas B, Savitt JM, Lim KL, Sasaki M, Hess EJ, Dawson VL, Dawson TM.

Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10744-9. Epub 2004 Jul 12.

Supplemental Content

Support Center